Standard Chartered CEO Apologizes After Referring to Workers as Lower Value Human Capital Meta Rolls Out AI Subscription Plans Starting at 799 Monthly in New Testing Phase Forum Energy Technologies FET Reports 8 Revenue Growth in First Quarter Huawei Unveils New Chip Design Approach Ahead of Fall Launch Challenging Nvidia and Apple Estate Planning Dilemma Can Family Cash Out CDs of Father in Hospice Care Veralto Corporation Stock Outlook Wall Street Sentiment Remains Divided LMAT Q1 2026 Earnings Modest EPS Beat Amid Revenue Data Gap OrthoPediatrics Corp KIDS Q1 2026 Earnings NarrowerThanExpected Loss Surprises Market TXO Partners LP Q1 2026 Earnings Deep Loss Per Unit Fails to Deter Investors Stock Gains 393 RCUS Q1 2026 Earnings WiderthanExpected Loss Highlights Ongoing Biotech Development Costs CRVL Q1 2026 Earnings EPS of 061 Exceeds Expectation Stock Declines 269 ROIV Q1 2026 Earnings WiderThanExpected Loss Highlights PreRevenue Pipeline Costs GrowGeneration Corp GRWG Modest Gains Amid Key Technical Test Golden Sun Technology Group GSUN Rises 37 as Stock Tests Key Resistance Zone Royalty Pharma RPRX Holds Ground Near Midpoint Steady Trading in Tight Range Enhabit Inc EHAB Edges Higher Amid Tight Trading Range Nexentis Technologies NXTS Surges 51 Key Levels and Volume Patterns Signal Potential Breakout SpaceX IPO Speculation Nvidia Earnings and Bezos AI Comments Highlight Morning Market Briefing OptimizeRx OPRX Q1 2026 Earnings Massive EPS Beat Sends Stock Higher Highwoods Properties HIW Edges Higher as Real Estate Sector Shows Signs of Stabilization Safe Bulkers Inc SB Surges 320 as Dry Bulk Shipping Sentiment Improves cbdMD Inc YCBD Slightly Lower as Stock Hovers Near Key Support at 071 Voya Infrastructure Industrials and Materials Fund IDE Holds Gains Testing Key Technical Zone Weyco Group Inc WEYS Holds Steady Near Resistance Modest Gains Amid Consolidation XMAX Inc XWIN Holds Steady at 824 as Market Awaits Catalyst SkyWater Technology SKYT Edges Higher as Semiconductor Foundry Stock Tests Key Resistance Akebia Therapeutics AKBA Holds Steady at 102 as Stock Consolidates Near Key Support